Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

NCT00164892 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.

NCT NCT00164892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00164892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial
Lead sponsor
Chinese University of Hong Kong
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2004
Completion date
Not reported
Enrollment
214
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of stomach